Conference on CNS Clinical Trials 2010

Neurological disorders and Central Nervous System (CNS) diseases are reported to account for one third of the world's disease burden. Due to the correlation with the aging population and these diseases this statistic is projected to increase rapidly in the coming years. As such, the market for CNS drugs was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007.

However, clinical trials for Neurological disorders are very complex compared to most therapeutic areas with many additional challenges such as recruiting mentally unstable subjects and understanding their pain response.

Through extensive research with industry experts, VIBpharma’s CNS Clinical Trials conference reveals how to tackle such issues. A series of case study based presentations and interactive discussions will cover key priorities such as accelerating and improving patient recruitment and retention, bridging the gap between pre-clinical and clinical CNS trials, optimising CNS trial design and management, utilising emerging technologies to monitor the clinical drug effect, designing effective adaptive trials in CNS.